This project is designed to test a central hypothesis that silencing the master immune negative regulator MSK (mitogen- and stress-activated protein kinase) in dendritic cells will allow them to be fully activated by MSLN-VLP stimulation, significantly increasing the active immune response and eliminating the suppressive immune response. This would increase the therapeutic efficiency of the DC vaccine against pancreatic cancer in the mouse model.
Two specific aims are proposed: 1) To determine critical roles of MSKs in DC antigen presentation, cytokine production, and T cell stimulation in vitro. We hypothesize that blocking the MSK1 and MSK2 genes in DCs will enhance DC activation and the Ag-presentation property;it will also reduce immune suppressive cytokine production, and reduce Treg production. 2) To determine the active immune response induction and therapeutic efficacy of DC vaccine with MSK silencing and MSLN-VLP stimulation in the mouse models of pancreatic cancer. We hypothesize that DC vaccine with MSK silencing and MSLN-VLP stimulation could induce stronger active immune responses and efficiently control pancreatic cancer progression in the orthotopic implant pancreatic cancer mouse model. Overall, we expect these studies to contribute significantly to our knowledge of pancreatic cancer vaccine development with immediate implications in therapeutic treatment of human pancreatic cancer.

Public Health Relevance

The incidence of pancreatic cancer remains equal to the mortality rate, new approaches to the treatment of pancreatic cancer are urgently needed. This project is designed to develop a novel virus-like particle (VLP) stimulated dendritic cell (DC) immunotherapeutic vaccine for pancreatic cancer. By blocking the immune inhibitory factors in DC, this vaccine may have an enhanced ability to process tumor antigens and generate tumor-specific response biased immunity, thereby enhancing the efficacy of VLP immunotherapy against pancreatic cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA140828-02
Application #
7843678
Study Section
Transplantation, Tolerance, and Tumor Immunology (TTT)
Program Officer
Welch, Anthony R
Project Start
2009-05-17
Project End
2012-04-30
Budget Start
2010-05-01
Budget End
2012-04-30
Support Year
2
Fiscal Year
2010
Total Cost
$202,620
Indirect Cost
Name
Baylor College of Medicine
Department
Surgery
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Marin-Muller, Christian; Li, Dali; Bharadwaj, Uddalak et al. (2013) A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer. Clin Cancer Res 19:5901-13
Zhang, Sheng; Yong, Lin-Kin; Li, Dali et al. (2013) Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS- regulatory T cells. PLoS One 8:e68303
Bharadwaj, Uddalak; Marin-Muller, Christian; Li, Min et al. (2011) Mesothelin confers pancreatic cancer cell resistance to TNF-*-induced apoptosis through Akt/PI3K/NF-*B activation and IL-6/Mcl-1 overexpression. Mol Cancer 10:106
Weakley, Sarah M; Wang, Hao; Yao, Qizhi et al. (2011) Expression and function of a large non-coding RNA gene XIST in human cancer. World J Surg 35:1751-6
Chen, Changyi; Zhang, Yuqing; Zhang, Lidong et al. (2011) MicroRNA-196: critical roles and clinical applications in development and cancer. J Cell Mol Med 15:14-23
Bharadwaj, Uddalak; Marin-Muller, Christian; Li, Min et al. (2011) Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 32:1013-24
Zhang, Lidong; Jamaluddin, Md Saha; Weakley, Sarah M et al. (2011) Roles and mechanisms of microRNAs in pancreatic cancer. World J Surg 35:1725-31
Lu, Jian-Ming; Nurko, Jacobo; Weakley, Sarah M et al. (2010) Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update. Med Sci Monit 16:RA93-100